Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:

NCT ID: NCT03481270 Completed - Influenza Clinical Trials

The Oakland Men's Health Disparities Study

Start date: October 14, 2017
Phase: N/A
Study type: Interventional

Reducing racial disparities in health outcomes is a major policy concern in the United States. Although there has been recent progress to close the gap, black men continue to experience earlier morbidity and mortality from preventable and manageable medical conditions, and live on average 4.2 years less than their white male peers. An oft-prescribed solution to close this stubborn gap is to increase the diversity of the healthcare workforce. Another common policy tool to increase take-up of preventative healthcare services is financial incentives. In this randomized evaluation, we will estimate the effects of financial incentives and a racially concordant physician on the uptake of preventive health services in Oakland, California.

NCT ID: NCT03474887 Recruiting - Influenza Clinical Trials

Digital Online Consultations - Effects on Antibiotic Prescribing in Primary Care

DOC-APP
Start date: March 30, 2018
Phase:
Study type: Observational

BACKGROUND/SIGNIFICANCE: With developments in mobile health and the abundance of smartphones, online consultations have emerged as a popular form of primary care in Sweden. Controversy exists regarding diagnostic accuracy, appropriate prescription of antibiotics, and effects on care-seeking patient behavior following implementation of online consultations. As empirical research is lacking, the investigators seek to evaluate online primary care consultations compared to physical consultations with regards to non-inferiority of antibiotic prescription for chief complaint of sore throat. METHODS: Medical record data is used to identify patients with a chief complaint of sore throat, cough/common cold/influenza, or dysuria after choosing online (DIGI) or physical (PHYSI) consultations. A cohort of patients with similar chief complaints prior to implementation of online consultations was used as a control group (CONTROL). Prospective data from local registries and medical records was gathered 14 days the consultation. The primary outcome was rate of antibiotic prescription after sore throat. Secondary outcomes included patient revisits (including hospital admissions), patient satisfaction, time to physician contact, registered diagnosis, and documentation or Centor Criteria and Urinary Tract Infection (UTI)-Criteria. SIGNIFICANCE: Results will shed light on whether antibiotic prescription differs significantly between digital and physical primary care consultations. Hypotheses may also be generated as to how patients seek care in light of improved availability in a tax-sponsored healthcare system.

NCT ID: NCT03459391 Completed - Influenza Clinical Trials

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Start date: May 22, 2017
Phase: Phase 1
Study type: Interventional

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of drug XC221 after single and repeated oral administration in healthy volunteers. The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break. The primary objective of the study was to evaluate the safety and tolerability profile for drug XC221 after single and multiple administration based on the frequency and severity of adverse events and changes in vital signs, laboratory results, electrocardiography and results of the physical examination. The secondary objective of the study was to assess pharmacokinetics of active pharmaceutical substance XC221GI and its metabolite XC221A.

NCT ID: NCT03455491 Recruiting - Influenza Clinical Trials

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs. placebo in patients with uncomplicated influenza or other ARVI during a 3-day treatment. The primary objective of the study is to demonstrate the difference in time before the onset of a sustained improvement in clinical symptoms according to the Modified Jackson Scale for ARVI and to determine the optimal dose of XC221 in the treatment of influenza and other ARVI.

NCT ID: NCT03453801 Recruiting - Healthy Clinical Trials

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

SLVP030
Start date: August 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.

NCT ID: NCT03451656 Completed - Influenza Clinical Trials

Prospective System Analysis of the Seasonal Influenza Virus Transmissions and Evolution in the City of Basel Basel

me15Egli2_CTU
Start date: December 27, 2016
Phase: N/A
Study type: Observational

The project aims to use epidemiological tools to understand the transmission and evolution of influenza viruses at an individual and population level within a small-scale city (Basel) through a combination of experimental, clinical, and mathematical advances. Investigators aim to quantitatively characterize the viral transmission using novel molecular-epidemiological tools based on whole genome sequencing.

NCT ID: NCT03450915 Not yet recruiting - Influenza Clinical Trials

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

Start date: August 2018
Phase: Phase 3
Study type: Interventional

The pivotal Phase 3 trial plans to enroll a total of 9,630 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then followed for up to 2 seasons. The trial will evaluate the number of influenza cases in each group and the severity of illness during the follow up period.

NCT ID: NCT03448705 Recruiting - Influenza Clinical Trials

Safety of 4Fluart Intradermal Suspension for Injection (Influenza Vaccine, Whole-virion, Inactivated, Adjuvanted) in Adult Subjects

Start date: January 31, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safe usability of the study drugs, i.e. 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of safety concerns emerged. The secondary objective of the study is to further assess safety in terms of safety parameters, as well as to assess the immunogenicity of 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of immunogenicity parameters.

NCT ID: NCT03441373 Completed - Influenza Clinical Trials

XC8 in the Treatment of Patients With Acute Respiratory Viral Infection

Start date: February 3, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

A multicenter double-blind, randomized, placebo-controlled, parallel-group comparative Phase II / III clinical study to assess safety, tolerability, efficacy and optimal dose ranging of XC8 vs. placebo in patients with uncomplicated influenza or other ARVI during a 5-day treatment. The primary objective of the study was to demonstrate the difference in time before the onset of a sustained improvement in clinical symptoms according to the Severity Rating Scale for ARVI, and to determine the optimal dose of XC8 in the treatment of influenza and other ARVI.

NCT ID: NCT03437304 Active, not recruiting - Influenza Clinical Trials

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults

Start date: February 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years) following Immunose™ FLU vaccination at 5 sites in Sweden. A total of 300 subjects will be randomised to 1 of 7 treatment groups. The hypothesis is that Immunose™ FLU is safe and tolerable and will increase the influenza-specific mucosal immune response in older adults.